Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus.

Tello-Montoliu A, Ferreiro JL, Kodali MK, Ueno M, Tomasello SD, Rollini F, Capodanno D, Darlington A, Patel R, Desai B, Guzman LA, Bass TA, Angiolillo DJ.

J Thromb Thrombolysis. 2013 Jul;36(1):14-7. doi: 10.1007/s11239-012-0828-1.

PMID:
23143668
2.

Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.

Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A.

J Am Coll Cardiol. 2010 Mar 16;55(11):1139-46. doi: 10.1016/j.jacc.2009.10.043.

3.

Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.

Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F, Ueno M, Darlington A, Desai B, Moser BA, Sugidachi A, Guzman LA, Bass TA.

J Am Coll Cardiol. 2014 Sep 9;64(10):1005-14. doi: 10.1016/j.jacc.2014.06.1170.

4.

Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.

Darlington A, Tello-Montoliu A, Rollini F, Ueno M, Ferreiro JL, Patel R, Desai B, Guzman LA, Bass TA, Angiolillo DJ.

Thromb Haemost. 2014 Feb;111(2):258-65. doi: 10.1160/TH13-07-0529. Epub 2013 Oct 24.

PMID:
24154863
5.

Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Rollini F, Tello-Montoliu A, Patel R, Darlington A, Wilson RE, Franchi F, Muñiz-Lozano A, Desai B, Bender N, Sakariassen KS, Angiolillo DJ.

J Thromb Thrombolysis. 2014;37(2):131-8. doi: 10.1007/s11239-013-0979-8.

PMID:
23943337
6.

Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.

Ueno M, Ferreiro JL, Tomasello SD, Tello-Montoliu A, Capodanno D, Seecheran N, Kodali M, Dharmashankar K, Desai B, Charlton RK, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2011 Aug;4(8):905-12. doi: 10.1016/j.jcin.2011.05.016.

7.

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.

Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB.

Eur Heart J. 2011 Apr;32(7):838-46. doi: 10.1093/eurheartj/ehq494. Epub 2011 Jan 20.

8.

[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].

Morel O, Viellard C, Faure A, Jesel L, Ohlmann P, Desprez D, Chauvin M, Roul G, Grunebaum L, Bareiss P.

Ann Cardiol Angeiol (Paris). 2007 Jan;56(1):21-9. French.

PMID:
17343035
9.

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.

Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA.

Circulation. 2007 Feb 13;115(6):708-16. Epub 2007 Jan 29.

10.

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.

Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ.

Thromb Haemost. 2008 Jan;99(1):215-22. doi: 10.1160/TH07-09-0555.

PMID:
18217157
11.

Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.

Liang Y, Johnston M, Hirsh J, Pare G, Li C, Mehta S, Teo KK, Sloane D, Yi Q, Zhu J, Eikelboom JW.

J Thromb Thrombolysis. 2012 Nov;34(4):429-36. doi: 10.1007/s11239-012-0762-2. Erratum in: J Thromb Thrombolysis. 2013 Jan;35(1):130.

PMID:
22797934
12.

Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.

Stellbaum C, Ayral Y, Morguet A, Schultheiss HP, Rauch U.

Cardiovasc Revasc Med. 2012 May-Jun;13(3):159-66. doi: 10.1016/j.carrev.2012.02.009. Epub 2012 Apr 14.

PMID:
22503564
13.

Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.

Kim IS, Jeong YH, Tantry US, Park Y, Lee DH, Bliden KP, Koh JS, Park JR, Jang JS, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S, Gurbel PA.

Am Heart J. 2013 Jul;166(1):95-103. doi: 10.1016/j.ahj.2013.03.030. Epub 2013 May 6.

PMID:
23816027
14.

Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention.

Motovska Z, Odvodyova D, Fischerova M, Stepankova S, Maly M, Morawska P, Widimsky P.

Am J Cardiol. 2012 Mar 1;109(5):620-3. doi: 10.1016/j.amjcard.2011.10.019. Epub 2011 Dec 10.

PMID:
22154314
15.

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.

Franchi F, Rollini F, Aggarwal N, Hu J, Kureti M, Durairaj A, Duarte VE, Cho JR, Been L, Zenni MM, Bass TA, Angiolillo DJ.

Circulation. 2016 Sep 13;134(11):780-92. doi: 10.1161/CIRCULATIONAHA.116.023402. Epub 2016 Aug 24.

PMID:
27559041
16.

Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.

Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, Darlington A, Desai B, Tello-Montoliu A, Rollini F, Angiolillo DJ.

Catheter Cardiovasc Interv. 2013 Jan 1;81(1):42-9. doi: 10.1002/ccd.24416. Epub 2012 Apr 17.

PMID:
22431415
18.

Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.

Suryadevara S, Ueno M, Tello-Montoliu A, Ferreiro JL, Desai B, Rollini F, Box LC, Zenni M, Guzman LA, Bass TA, Angiolillo DJ.

Thromb Haemost. 2012 Nov;108(5):930-6. doi: 10.1160/TH12-06-0397. Epub 2012 Jul 10.

PMID:
22782352
19.

The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.

Dropinski J, Jakiela B, Sanak M, Wegrzyn W, Biernat M, Dziedzina S, Plutecka H, Szczeklik A.

Thromb Haemost. 2007 Jul;98(1):201-9.

PMID:
17598014
20.

Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.

Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J.

Thromb Haemost. 2008 Jul;100(1):76-82. doi: 10.1160/TH08-03-0136.

PMID:
18612541

Supplemental Content

Support Center